Fifth Circuit Overturns DEA Corresponding Responsibility Rule

Fifth Circuit Overturns DEA's Pharmacist 'Corresponding Responsibility' Interpretation—What Distributors Need to Know

On January 7, 2025, the U.S. Court of Appeals for the Fifth Circuit vacated a DEA enforcement action against pharmacist Steven Chen, ruling that the agency exceeded its statutory authority by imposing "corresponding responsibility" standards on pharmacy dispensing decisions. The decision directly affects how wholesale drug distributors assess downstream pharmacy compliance under 21 CFR § 1301.74(b), which requires distributors to design systems that detect suspicious orders of controlled substances.

Regulatory Background

Under the Controlled Substances Act (21 U.S.C. § 823(b)), DEA has authority to regulate the distribution of controlled substances. DEA's corresponding responsibility doctrine—derived from 21 CFR § 1306.04(a)—historically held that pharmacists share responsibility with prescribers to ensure prescriptions are issued for legitimate medical purposes. DEA extended this doctrine to distributors in Cardinal Health v. Holder (2012), establishing that distributors cannot willfully ignore red flags in downstream pharmacy ordering patterns.

The Fifth Circuit's ruling in Chen v. DEA challenges DEA's interpretation of "legitimate medical purpose" under § 1306.04(a). The court held that DEA improperly required pharmacists to exercise clinical judgment about prescription validity—a responsibility the statute assigns to prescribers. The court's reasoning: "A pharmacist's corresponding responsibility extends to verifying the prescription's facial validity and the prescriber's authority, not to second-guessing the prescriber's medical judgment."

What Changed

The Fifth Circuit distinguished between two types of pharmacy compliance assessments:

1. Facial validity checks — Verifying the prescription contains required elements (patient name, prescriber signature, DEA number, drug name, quantity, directions). DEA retains authority to enforce these checks under 21 CFR § 1306.05.

1. Medical necessity assessments — Evaluating whether the prescription serves a legitimate medical purpose based on dosage, combination therapy, or diagnosis. DEA cannot require pharmacists to perform these assessments absent clear statutory authority.

The ruling does not eliminate corresponding responsibility. It narrows DEA's enforcement discretion to objective prescription defects—missing information, invalid DEA numbers, obvious forgeries—rather than subjective clinical judgments.

Impact on Distributor Suspicious Order Monitoring

Wholesale drug distributors maintain suspicious order monitoring systems under 21 CFR § 1301.74(b) and the Registrant Settlement Agreement framework established after the 2017 McKesson, Cardinal Health, and AmerisourceBergen consent decrees. These systems flag pharmacy customers whose order patterns deviate from expected norms based on factors including:

• Order volume relative to pharmacy size
• Frequency of high-risk controlled substances (oxycodone, hydrocodone, fentanyl)
• Geographic anomalies (pharmacies ordering quantities inconsistent with local patient populations)
• Ratio of brand-name to generic opioids

The Fifth Circuit ruling affects how distributors interpret downstream pharmacy order patterns. If a pharmacy's orders trigger thresholds but the pharmacy can demonstrate valid prescriptions on file, distributors may have reduced exposure under DEA enforcement actions that rely on "corresponding responsibility" theories.

However, distributors cannot ignore objective red flags. The ruling preserves DEA authority to enforce against distributors who:

• Fill orders for pharmacies with revoked or suspended DEA registrations
• Continue shipping after receiving formal DEA suspension notices
• Fail to investigate pharmacies filling prescriptions from prescribers with known disciplinary actions

The practical question: does a pharmacy ordering 200% above state per-capita averages constitute a red flag requiring distributor action, or does the Fifth Circuit's reasoning insulate that pharmacy if prescriptions are facially valid? DEA guidance has not yet addressed this distinction post-Chen.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain providers. DEA registration data is not currently included in compliance scores—ColdChainCheck has applied for access via the RDA process—but the Fifth Circuit ruling affects how entities with active DEA registrations evaluate downstream pharmacy relationships.

Of the 1,275 entities in the directory, 1,234 hold active FDA establishment registrations. The average compliance score is 51/100, with 919 entities (72%) in the "Fair" tier. This distribution suggests most distributors maintain basic state licensure and federal registration but lack comprehensive third-party accreditation signals. NABP accreditation—held by only 63 entities—includes evaluation of suspicious order monitoring systems, making accredited distributors more likely to have formalized processes for downstream pharmacy risk assessment.

The 73 entities with FDA recalls on record include cases involving distribution to pharmacies later found to have invalid DEA registrations or suspended licenses. Post-Chen, distributors should review whether their suspicious order monitoring procedures distinguish between objective red flags (invalid DEA numbers, suspended registrations) and subjective clinical assessments (high order volumes for legitimately prescribed controlled substances).

Practical Guidance for Compliance Officers

• Review existing SOPs for suspicious order monitoring. If procedures require distributors to assess "medical necessity" or "appropriate prescribing patterns," revise to focus on objective prescription defects and registration validity. The Fifth Circuit ruling does not protect distributors who ignore facially invalid orders.

• Audit downstream pharmacy verification processes. Use ColdChainCheck's directory to cross-reference pharmacy customers against state board of pharmacy databases. Confirm active licenses and check for enforcement actions. A pharmacy with a clean license record and valid DEA registration has stronger standing under the Chen interpretation.

• Document red flag investigations. If a pharmacy's order pattern triggers internal thresholds, document the investigation process: prescription review, prescriber verification, and rationale for approving or rejecting the order. Post-Chen, DEA may scrutinize whether distributors applied objective criteria versus subjective clinical judgment.

• Monitor DEA guidance updates. DEA has not issued formal guidance responding to the Fifth Circuit ruling. Distributors operating in the Fifth Circuit (Texas, Louisiana, Mississippi) should consult legal counsel before modifying suspicious order procedures. Distributors in other circuits remain subject to existing DEA interpretations until appellate courts rule otherwise.

ColdChainCheck will update the compliance guides section as DEA releases post-Chen enforcement clarifications.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Wholesale drug distributors should consult legal counsel and verify all regulatory requirements with the DEA and applicable state boards of pharmacy.